Treating TTR amyloidosis - early diagnosis is essential

Affiliations

Editorial

Mary M Reilly. J Neurol Neurosurg Psychiatry. 2024.

. 2024 May 14;95(6):488.

doi: 10.1136/jnnp-2023-332841.

¹ Institute of Neurology and National Hospital for Neurology and Neurosurgery, UCL, London, WC1H 9BT, UK m.reilly@ucl.ac.uk.

No abstract available

Keywords: NEUROPATHY.

Conflict of interest statement

Competing interests: None declared.

Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers.
Beauvais D, Labeyrie C, Cauquil C, Francou B, Eliahou L, Not A, Echaniz-Laguna A, Adam C, Slama MS, Benmalek A, Leonardi L, Rouzet F, Adams D, Algalarrondo V, Beaudonnet G. Beauvais D, et al. J Neurol Neurosurg Psychiatry. 2024 May 14;95(6):489-499. doi: 10.1136/jnnp-2023-332180. J Neurol Neurosurg Psychiatry. 2024. PMID: 37875336 Free PMC article.